Clozapine in drug induced psychosis in Parkinson’s disease: a randomised, placebo controlled study with open follow up
Identifieur interne : 000F29 ( Main/Curation ); précédent : 000F28; suivant : 000F30Clozapine in drug induced psychosis in Parkinson’s disease: a randomised, placebo controlled study with open follow up
Auteurs : P. Pollak [France] ; F. Tison [France] ; O. Rascol [France] ; A. Destée [France] ; J J Péré [France] ; J M Senard [France] ; F. Durif [France] ; I. Bourdeix [France]Source :
- Journal of Neurology, Neurosurgery & Psychiatry [ 0022-3050 ] ; 2004-05.
English descriptors
- KwdEn :
Abstract
Objective: To compare the efficacy and safety of clozapine in drug induced psychosis in Parkinson’s disease (PD). Methods: A four week, randomised, double blind, parallel comparison of clozapine and placebo, followed by a 12 week clozapine open period, plus a one month period after drug discontinuation, in 60 patients with PD. The primary efficacy outcome was the “clinical global impression scale” (CGI); the positive subscore of the “positive and negative syndrome scale” (PANSS) was used as the secondary efficacy parameter and the “unified Parkinson’s disease rating scale” (UPDRS) and the “mini mental test examination” (MMSE) as safety outcomes. Results: The mean (SD) dosage of clozapine was 35.8 (12.5–50) mg at the end of the double blind period. The mean (SD) scores on the CGI improved by 1.8 (1.5) for the clozapine group compared with 0.6 (1.1) for the placebo group (p = 0.001). The mean (SD) positive subscore of PANSS improved by 5.6 (3.9) for the clozapine group (0.8 (2.8) for the placebo group; p < 0.0001). At the end of the open period, 25 patients had completely recovered from delusions and hallucinations, and 19 experienced a relapse within one month after the clozapine washout period. The UPDRS motor and MMSE mean scores did not change significantly in either group. Somnolence was more frequent with clozapine than with placebo. Conclusions: Clozapine at a mean dose lower than 50 mg/day improves drug induced psychosis in PD without significant worsening of motor function, and the effect wears off once the treatment stops.
Url:
DOI: 10.1136/jnnp.2003.029868
Links toward previous steps (curation, corpus...)
- to stream Main, to step Corpus: Pour aller vers cette notice dans l'étape Curation :001123
Links to Exploration step
ISTEX:D8CE96F619CD308F9DD33D29A5CCFC4FF3A19292Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Clozapine in drug induced psychosis in Parkinson’s disease: a randomised, placebo controlled study with open follow up</title><author><name sortKey="Pollak, P" sort="Pollak, P" uniqKey="Pollak P" first="P" last="Pollak">P. Pollak</name><affiliation wicri:level="1"><mods:affiliation>Department of Neurology, University Hospital of Grenoble, 38043 Grenoble Cedex 9, France</mods:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Department of Neurology, University Hospital of Grenoble, 38043 Grenoble Cedex 9</wicri:regionArea></affiliation></author><author><name sortKey="Tison, F" sort="Tison, F" uniqKey="Tison F" first="F" last="Tison">F. Tison</name><affiliation wicri:level="1"><mods:affiliation>Fédération de Neurologie, University Hospital of Bordeaux, 33604 Pessac, France</mods:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Fédération de Neurologie, University Hospital of Bordeaux, 33604 Pessac</wicri:regionArea></affiliation></author><author><name sortKey="Rascol, O" sort="Rascol, O" uniqKey="Rascol O" first="O" last="Rascol">O. Rascol</name><affiliation wicri:level="1"><mods:affiliation>Clinical Investigation Centre, Department of Clinical Pharmacology, INSERM U455, CHU Purpan, 31073 Toulouse University Hospital, France</mods:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Clinical Investigation Centre, Department of Clinical Pharmacology, INSERM U455, CHU Purpan, 31073 Toulouse University Hospital</wicri:regionArea></affiliation></author><author><name sortKey="Destee, A" sort="Destee, A" uniqKey="Destee A" first="A" last="Destée">A. Destée</name><affiliation wicri:level="1"><mods:affiliation>Neurology and Movement Disorders Unit, Neurologie A, Hôpital Salengro, 59037 Lille, France</mods:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Neurology and Movement Disorders Unit, Neurologie A, Hôpital Salengro, 59037 Lille</wicri:regionArea></affiliation></author><author><name sortKey="Pere, J J" sort="Pere, J J" uniqKey="Pere J" first="J J" last="Péré">J J Péré</name><affiliation wicri:level="1"><mods:affiliation>Novartis Pharma, 92506 Rueil-Malmaison, France</mods:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Novartis Pharma, 92506 Rueil-Malmaison</wicri:regionArea></affiliation></author><author><name sortKey="Senard, J M" sort="Senard, J M" uniqKey="Senard J" first="J M" last="Senard">J M Senard</name><affiliation wicri:level="1"><mods:affiliation>Clinical Investigation Centre, Department of Clinical Pharmacology, INSERM U455, CHU Purpan, 31073 Toulouse University Hospital, France</mods:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Clinical Investigation Centre, Department of Clinical Pharmacology, INSERM U455, CHU Purpan, 31073 Toulouse University Hospital</wicri:regionArea></affiliation></author><author><name sortKey="Durif, F" sort="Durif, F" uniqKey="Durif F" first="F" last="Durif">F. Durif</name><affiliation wicri:level="1"><mods:affiliation>Fédération de Neurologie, Hôpital Gabriel Montpied, 63033 Clermont-Ferrand Cedex I, France</mods:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Fédération de Neurologie, Hôpital Gabriel Montpied, 63033 Clermont-Ferrand Cedex I</wicri:regionArea></affiliation></author><author><name sortKey="Bourdeix, I" sort="Bourdeix, I" uniqKey="Bourdeix I" first="I" last="Bourdeix">I. Bourdeix</name><affiliation wicri:level="1"><mods:affiliation>Novartis Pharma, 92506 Rueil-Malmaison, France</mods:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Novartis Pharma, 92506 Rueil-Malmaison</wicri:regionArea></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:D8CE96F619CD308F9DD33D29A5CCFC4FF3A19292</idno><date when="2004" year="2004">2004</date><idno type="doi">10.1136/jnnp.2003.029868</idno><idno type="url">https://api.istex.fr/document/D8CE96F619CD308F9DD33D29A5CCFC4FF3A19292/fulltext/pdf</idno><idno type="wicri:Area/Main/Corpus">001123</idno><idno type="wicri:Area/Main/Curation">000F29</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Clozapine in drug induced psychosis in Parkinson’s disease: a randomised, placebo controlled study with open follow up</title><author><name sortKey="Pollak, P" sort="Pollak, P" uniqKey="Pollak P" first="P" last="Pollak">P. Pollak</name><affiliation wicri:level="1"><mods:affiliation>Department of Neurology, University Hospital of Grenoble, 38043 Grenoble Cedex 9, France</mods:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Department of Neurology, University Hospital of Grenoble, 38043 Grenoble Cedex 9</wicri:regionArea></affiliation></author><author><name sortKey="Tison, F" sort="Tison, F" uniqKey="Tison F" first="F" last="Tison">F. Tison</name><affiliation wicri:level="1"><mods:affiliation>Fédération de Neurologie, University Hospital of Bordeaux, 33604 Pessac, France</mods:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Fédération de Neurologie, University Hospital of Bordeaux, 33604 Pessac</wicri:regionArea></affiliation></author><author><name sortKey="Rascol, O" sort="Rascol, O" uniqKey="Rascol O" first="O" last="Rascol">O. Rascol</name><affiliation wicri:level="1"><mods:affiliation>Clinical Investigation Centre, Department of Clinical Pharmacology, INSERM U455, CHU Purpan, 31073 Toulouse University Hospital, France</mods:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Clinical Investigation Centre, Department of Clinical Pharmacology, INSERM U455, CHU Purpan, 31073 Toulouse University Hospital</wicri:regionArea></affiliation></author><author><name sortKey="Destee, A" sort="Destee, A" uniqKey="Destee A" first="A" last="Destée">A. Destée</name><affiliation wicri:level="1"><mods:affiliation>Neurology and Movement Disorders Unit, Neurologie A, Hôpital Salengro, 59037 Lille, France</mods:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Neurology and Movement Disorders Unit, Neurologie A, Hôpital Salengro, 59037 Lille</wicri:regionArea></affiliation></author><author><name sortKey="Pere, J J" sort="Pere, J J" uniqKey="Pere J" first="J J" last="Péré">J J Péré</name><affiliation wicri:level="1"><mods:affiliation>Novartis Pharma, 92506 Rueil-Malmaison, France</mods:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Novartis Pharma, 92506 Rueil-Malmaison</wicri:regionArea></affiliation></author><author><name sortKey="Senard, J M" sort="Senard, J M" uniqKey="Senard J" first="J M" last="Senard">J M Senard</name><affiliation wicri:level="1"><mods:affiliation>Clinical Investigation Centre, Department of Clinical Pharmacology, INSERM U455, CHU Purpan, 31073 Toulouse University Hospital, France</mods:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Clinical Investigation Centre, Department of Clinical Pharmacology, INSERM U455, CHU Purpan, 31073 Toulouse University Hospital</wicri:regionArea></affiliation></author><author><name sortKey="Durif, F" sort="Durif, F" uniqKey="Durif F" first="F" last="Durif">F. Durif</name><affiliation wicri:level="1"><mods:affiliation>Fédération de Neurologie, Hôpital Gabriel Montpied, 63033 Clermont-Ferrand Cedex I, France</mods:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Fédération de Neurologie, Hôpital Gabriel Montpied, 63033 Clermont-Ferrand Cedex I</wicri:regionArea></affiliation></author><author><name sortKey="Bourdeix, I" sort="Bourdeix, I" uniqKey="Bourdeix I" first="I" last="Bourdeix">I. Bourdeix</name><affiliation wicri:level="1"><mods:affiliation>Novartis Pharma, 92506 Rueil-Malmaison, France</mods:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Novartis Pharma, 92506 Rueil-Malmaison</wicri:regionArea></affiliation></author></analytic><monogr></monogr><series><title level="j">Journal of Neurology, Neurosurgery & Psychiatry</title><title level="j" type="abbrev">J Neurol Neurosurg Psychiatry</title><idno type="ISSN">0022-3050</idno><idno type="eISSN">1468-330X</idno><imprint><publisher>BMJ Publishing Group Ltd</publisher><date type="published" when="2004-05">2004-05</date><biblScope unit="volume">75</biblScope><biblScope unit="issue">5</biblScope><biblScope unit="page" from="689">689</biblScope></imprint><idno type="ISSN">0022-3050</idno></series><idno type="istex">D8CE96F619CD308F9DD33D29A5CCFC4FF3A19292</idno><idno type="DOI">10.1136/jnnp.2003.029868</idno><idno type="href">jnnp-75-689.pdf</idno><idno type="PMID">15090561</idno><idno type="local">0750689</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0022-3050</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>CGI, clinical global impression scale</term><term>MMSE, mini mental test examination</term><term>PANSS, positive and negative syndrome scale</term><term>PD, Parkinson’s disease</term><term>Parkinson’s disease</term><term>UPDRS, unified Parkinson’s disease rating scale</term><term>clozapine</term><term>psychosis</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Objective: To compare the efficacy and safety of clozapine in drug induced psychosis in Parkinson’s disease (PD). Methods: A four week, randomised, double blind, parallel comparison of clozapine and placebo, followed by a 12 week clozapine open period, plus a one month period after drug discontinuation, in 60 patients with PD. The primary efficacy outcome was the “clinical global impression scale” (CGI); the positive subscore of the “positive and negative syndrome scale” (PANSS) was used as the secondary efficacy parameter and the “unified Parkinson’s disease rating scale” (UPDRS) and the “mini mental test examination” (MMSE) as safety outcomes. Results: The mean (SD) dosage of clozapine was 35.8 (12.5–50) mg at the end of the double blind period. The mean (SD) scores on the CGI improved by 1.8 (1.5) for the clozapine group compared with 0.6 (1.1) for the placebo group (p = 0.001). The mean (SD) positive subscore of PANSS improved by 5.6 (3.9) for the clozapine group (0.8 (2.8) for the placebo group; p < 0.0001). At the end of the open period, 25 patients had completely recovered from delusions and hallucinations, and 19 experienced a relapse within one month after the clozapine washout period. The UPDRS motor and MMSE mean scores did not change significantly in either group. Somnolence was more frequent with clozapine than with placebo. Conclusions: Clozapine at a mean dose lower than 50 mg/day improves drug induced psychosis in PD without significant worsening of motor function, and the effect wears off once the treatment stops.</div></front></TEI></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonV1/Data/Main/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000F29 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Curation/biblio.hfd -nk 000F29 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= ParkinsonV1
|flux= Main
|étape= Curation
|type= RBID
|clé= ISTEX:D8CE96F619CD308F9DD33D29A5CCFC4FF3A19292
|texte= Clozapine in drug induced psychosis in Parkinson’s disease: a randomised, placebo controlled study with open follow up
}}
| This area was generated with Dilib version V0.6.23. |  |